CRISPR gene editing in 2026 is no longer a technology to watch. It is a technology delivering results. Across three distinct disease areas, rare inherited conditions, haematologic and solid cancers, and autoimmune disease, clinical programmes are accumulating meaningful data, regulatory frameworks are shifting to accommodate novel approaches, and a commercial market is beginning to take shape. The pace of change over the past twelve months has been striking.
Rare Diseases: A Regulatory Reset
The story that best captures the current moment in CRISPR gene editing is that of KJ Muldoon, a baby born in August 2024 with carbamoyl-phosphate synthetase 1 (CPS1) deficiency, an ultra-rare metabolic disorder affecting around one in 1.3 million live births. The condition prevents the liver from processing protein correctly, causing toxic ammonia to accumulate. Without intervention, half of affected infants do not survive their first year. Researchers at the Children’s Hospital of Philadelphia and Penn Medicine designed and delivered a bespoke base-editing therapy to Muldoon, with the first infusion administered in February 2025 when he was between six and seven months old, making him the first person in history to receive a personalised CRISPR-based gene therapy. As of early 2026, he is walking and showing only mild symptoms of a previously fatal condition.
The regulatory consequences have been immediate. In February 2026, the FDA published draft guidance introducing the “plausible mechanism framework,” a pathway designed specifically for individualised genomic therapies targeting ultra-rare diseases. The framework allows a single clinical trial to test a platform technology customised for each patient, without requiring a separate regulatory application for every unique genetic variant. For CRISPR, where the Cas9 protein and delivery system remain constant while only the guide RNA sequence changes between patients, this is a transformative change.
The framework was developed in the wake of cases like Muldoon’s. It requires that the underlying cause of the disease be understood at a genetic or cellular level and that the therapy demonstrably target that cause. Regulatory uncertainty persists following leadership departures at the FDA in mid-2026, but the pathway is already shaping commercial activity. Aurora Therapeutics, an eleven-person startup launched in January 2026, was founded explicitly to use this framework to develop CRISPR treatments for rare and ultra-rare conditions, targeting a first trial in 2027.
The broader rare disease market received further good news from the commercial front. Casgevy (exagamglogene autotemcel), the first approved CRISPR-based therapy, developed jointly by Vertex Pharmaceuticals and CRISPR Therapeutics for sickle cell disease and transfusion-dependent beta thalassaemia, generated $116 million in full-year 2025 revenue. Patient initiations as measured by first cell collection nearly tripled year-on-year. Reimbursed access now covers approximately 90% of eligible patients in the United States, and the therapy is reimbursed across the UK, Italy, Austria, Denmark, Luxembourg, and several Middle Eastern markets. At the American Society of Hematology annual meeting in December 2025, Vertex presented positive paediatric data from children aged 5 to 11, with all four children who had completed sufficient follow-up achieving freedom from vaso-occlusive crises for at least twelve consecutive months. Global regulatory submissions for this younger age group are expected in the first half of 2026.
Cancer: Off-the-Shelf CAR-T Gains Clinical Ground
The most advanced cancer application of CRISPR gene editing in 2026 centres on allogeneic CAR-T cell therapy, where CRISPR is used to remove genes that would otherwise cause donor T cells to attack the patient or be rejected. CRISPR Therapeutics’ lead oncology candidate, zugocaptagene geleucel (zugo-cel), targets the CD19 antigen and is being tested in patients with relapsed or refractory B-cell malignancies including large B-cell lymphoma, follicular lymphoma, marginal zone lymphoma, and mantle cell lymphoma. By late 2025, 39 patients had been treated across four dose levels, and the programme has now advanced into the Phase 2 portion of the trial. Updated data are expected in the second half of 2026. CRISPR Therapeutics has also entered a collaboration with Eli Lilly to evaluate zugo-cel alongside pirtobrutinib in aggressive B-cell lymphomas.
In solid tumours, where engineered CAR-T cells have historically struggled, early signals are beginning to emerge. Fate Therapeutics presented preliminary Phase 1 data at the ASCO Annual Meeting in late May 2026 for FT836, an off-the-shelf CAR-T therapy engineered from induced pluripotent stem cells and incorporating multiple genetic edits. Across the trial’s nine enrolled patients, two efficacy-evaluable patients with heavily pre-treated KRAS wild-type metastatic colorectal cancer, treated with FT836 in combination with cetuximab or trastuzumab, showed preliminary evidence of tumour reduction, with no dose-limiting toxicities, cytokine release syndrome, or graft-versus-host disease reported. Notably, FT836 was delivered without the lymphodepleting conditioning chemotherapy that has long been considered a prerequisite for CAR-T treatment, and the edited cells were detected within tumour tissue itself, suggesting effective infiltration and persistence.
Preclinical data published in late 2025 from Monash University and the Peter MacCallum Cancer Centre in Melbourne demonstrated that CRISPR-mediated deletion of the PTPN2 gene in CAR-T cells reduced tumour size and prolonged survival in mouse models of solid cancer. A PTPN2 inhibitor is already in early-phase human trials for solid tumours, raising the prospect of combining pharmacological and genetic approaches to overcome the immunosuppressive tumour microenvironment.
Autoimmune Disease: The Unexpected Frontier
The most surprising area of progress in CRISPR gene editing over the past year may be in autoimmune disease. The same allogeneic CAR-T strategy developed for B-cell cancers is now being applied to autoimmune conditions driven by aberrant B-cell populations, with early results that are attracting considerable attention.
CRISPR Therapeutics has dosed four participants (two with SLE and two with immune-mediated necrotizing myopathy) in a Phase 1 basket trial using CRISPR-edited allogeneic CAR-T cells targeting CD19, a trial that also includes systemic sclerosis and inflammatory myositis. No severe adverse events have been reported. All four patients showed significant clinical improvement at the Day 28 assessment, and one patient with SLE has maintained drug-free DORIS clinical remission through Month 6. A second Phase 1 basket trial has been initiated for autoimmune haematologic diseases, including immune thrombocytopenia and warm autoimmune haemolytic anaemia.
The underlying logic of this approach is compelling. In diseases like SLE, autoreactive B cells expressing CD19 drive the aberrant immune response. A CD19-directed CAR-T therapy depletes those B cells and, in doing so, may allow the immune system to reset. Because this is a “hit and run” strategy targeting immune depletion rather than ongoing tumour control, the therapy may be easier to deliver safely in autoimmune conditions than in cancers, where the persistent presence of immunotherapy is often necessary to maintain remission.
All autoimmune programmes currently in clinical development use allogeneic cells, manufactured from healthy donors and supplied as ready-to-use products without the need for HLA matching. This reduces both cost and production timelines substantially relative to autologous approaches, improving the prospects for broad patient access if these early results are confirmed in later-stage trials. More than a dozen global trials are now evaluating CAR-T therapy for SLE specifically, with CRISPR editing used across several programmes to improve T cell potency and reduce immune evasion.
Platform Maturation and the Road Ahead
The advances across all three disease areas reflect a technology that is transitioning from early proof-of-concept to genuine clinical maturation. According to the Innovative Genomics Institute’s March 2026 update, more than 150 CRISPR-related trials are now active globally, from a pool of approximately 250 tracked by the field’s specialist monitoring services. The field is simultaneously diversifying, with base editing, prime editing, and epigenetic editing platforms entering the clinic alongside the Cas9-based systems that defined CRISPR’s first decade. The progress has not been without cost. The field recorded its first patient death in a CRISPR trial when a participant receiving a bespoke Duchenne muscular dystrophy therapy died of acute respiratory distress syndrome, triggered by an immune response to the viral vector used to deliver the editing components, a reaction researchers noted could not have been predicted. It is a reminder that even highly targeted genomic medicine carries real and sometimes unforeseeable risk.
That broadening of the toolkit is happening against a difficult funding environment. Substantial cuts to US federal research budgets in 2025, including significant reductions in National Science Foundation and National Institutes of Health funding, have raised legitimate concerns about the basic science pipeline that will underpin future CRISPR programmes. How those pressures play out over the next several years will partly determine which of the many early-stage CRISPR approaches now in development will ultimately reach patients.
What is beyond question, in mid-2026, is that CRISPR gene editing has become a genuine clinical force across multiple therapeutic areas. The biology is complex, the challenges are real, and the regulatory environment is in flux. But the data are also accumulating in ways that would have been difficult to predict even five years ago
